GlobeStar Therapeutics Corporation (GSTC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GlobeStar Therapeutics Corporation (GSTC) trades at $0.0001 with AI Score 48/100 (Grade C). GlobeStar Therapeutics Corporation is a clinical-stage pharmaceutical company focused on developing treatments for multiple sclerosis and other neurodegenerative diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for GSTC: GSTC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GSTC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GSTC: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
GlobeStar Therapeutics Corporation (GSTC) Healthcare & Pipeline Overview
GlobeStar Therapeutics Corporation is a clinical-stage biotech firm specializing in patented drug formulations for neurodegenerative diseases like multiple sclerosis. Operating in a competitive biotechnology landscape, the company focuses on advancing its clinical pipeline and securing regulatory approvals to address unmet medical needs in neurological disorders.
What Is the Investment Thesis for GSTC?
GlobeStar Therapeutics Corporation presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. The company's value is largely tied to the successful development and commercialization of its patented drug formulation for multiple sclerosis and other neurodegenerative diseases. Key value drivers include positive clinical trial results, regulatory approvals from the FDA, and strategic partnerships with larger pharmaceutical companies. Upcoming catalysts include the progression of its lead drug candidate through clinical trials and potential data readouts. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for substantial additional funding. With a market capitalization of $0.00 billion and a negative P/E ratio of -0.04, the company's valuation is highly speculative and dependent on future success. Investors should carefully consider the inherent risks and uncertainties associated with investing in early-stage biotechnology companies before making any investment decisions.
Based on FMP financials and quantitative analysis
GSTC Key Highlights
GlobeStar Therapeutics Corporation is a clinical-stage pharmaceutical company focused on neurodegenerative diseases.
- The company's primary asset is a patented drug formulation targeting multiple sclerosis.
- GlobeStar Therapeutics Corporation changed its name from AngioSoma, Inc. in July 2021.
- The company has a beta of 1.42, indicating higher volatility compared to the market.
- GlobeStar Therapeutics Corporation does not currently pay a dividend.
Who Are GSTC's Competitors?
GSTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GSTC's Key Strengths?
Patented drug formulation.
- Focus on a large and growing market (neurodegenerative diseases).
- Experienced management team.
- Clinical-stage pipeline with potential for future revenue.
What Are GSTC's Weaknesses?
Limited financial resources.
- Dependence on successful clinical trial outcomes.
- No current revenue generation.
- High regulatory risk.
What Could Drive GSTC Stock Higher?
Clinical trial data readouts for the lead drug candidate in the next 12-24 months.
- Efforts to secure strategic partnerships with larger pharmaceutical companies.
- Advancement of the lead drug candidate through clinical trial phases.
What Are the Key Risks for GSTC?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could significantly impact the company's valuation.
- Regulatory hurdles and delays in obtaining FDA approval.
- Need for additional funding to support research and development activities.
- Competition from other pharmaceutical companies developing treatments for neurodegenerative diseases.
- Dependence on the success of a single drug candidate.
What Are the Growth Opportunities for GSTC?
- Advancement of Lead Drug Candidate: GlobeStar's primary growth opportunity lies in the successful advancement of its patented drug formulation through clinical trials. Positive results from Phase 2 and Phase 3 trials could significantly increase the company's valuation and attract potential partnerships. The market for multiple sclerosis treatments is projected to reach $30 billion by 2028, providing a substantial revenue opportunity for a successful therapy. Timeline: Ongoing clinical trials with potential data readouts in the next 12-24 months.
- Expansion of Pipeline: GlobeStar has the opportunity to expand its pipeline by developing additional drug candidates targeting other neurodegenerative diseases. This could diversify the company's risk and create multiple revenue streams. Timeline: Identification of new drug targets and initiation of preclinical studies within the next 2-3 years.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could provide GlobeStar with access to funding, expertise, and distribution channels. These partnerships could accelerate the development and commercialization of its drug candidates. Many large pharmaceutical companies are actively seeking to acquire or partner with smaller biotech firms with promising technologies. Timeline: Potential partnership discussions and agreements within the next 12-18 months.
- Regulatory Approvals: Securing regulatory approvals from the FDA and other regulatory agencies is critical for GlobeStar's success. Approval of its lead drug candidate would allow the company to commercialize the product and generate revenue. The regulatory approval process is lengthy and complex, but successful navigation of this process is essential for bringing new therapies to market. Timeline: Potential FDA approval within the next 3-5 years, assuming positive clinical trial results.
- Intellectual Property Protection: Strengthening and expanding its intellectual property portfolio is crucial for maintaining a competitive advantage. GlobeStar should continue to seek patents for its drug formulations and technologies. Strong intellectual property protection can deter competitors and increase the company's value. Timeline: Ongoing efforts to secure and defend patents related to its drug formulations.
What Are GSTC's Competitive Advantages?
- Patented drug formulations provide a degree of exclusivity.
- Clinical trial data can create a barrier to entry for competitors.
- Expertise in developing treatments for neurodegenerative diseases.
What Does GSTC Do?
GlobeStar Therapeutics Corporation, formerly known as AngioSoma, Inc., is a clinical-stage pharmaceutical company established in 2016 and based in Richland, Washington. The company is dedicated to the development of innovative therapies for neurodegenerative diseases, with a particular emphasis on multiple sclerosis. GlobeStar's core strategy revolves around a patented formulation of drugs designed to target the underlying mechanisms of these debilitating conditions. The company's evolution from AngioSoma to GlobeStar Therapeutics in July 2021 reflects a strategic shift towards a more focused approach on neurological therapeutics. The company operates within the highly competitive biotechnology sector, where it strives to differentiate itself through its proprietary drug formulations and clinical development programs. GlobeStar's geographic focus is primarily within the United States, where it conducts its research and development activities and seeks regulatory approvals for its products. As a clinical-stage company, GlobeStar Therapeutics does not currently have any products on the market. Its value is primarily derived from its intellectual property, clinical trial data, and the potential for future revenue generation upon successful commercialization of its drug candidates. The company's success hinges on its ability to navigate the complex regulatory landscape, secure funding for its research and development efforts, and demonstrate the safety and efficacy of its therapies in clinical trials.
What Products and Services Does GSTC Offer?
- Develop patented drug formulations for neurodegenerative diseases.
- Focus on treatments for multiple sclerosis.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Seek regulatory approvals from the FDA and other agencies.
- Explore strategic partnerships with larger pharmaceutical companies.
- Protect their intellectual property through patents and other means.
How Does GSTC Make Money?
- Develop and patent novel drug formulations.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval to commercialize drugs.
- Potentially partner with larger pharmaceutical companies for manufacturing and distribution.
What Industry Does GSTC Operate In?
GlobeStar Therapeutics Corporation operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for neurodegenerative disease treatments is substantial and growing, driven by an aging population and increasing prevalence of conditions like multiple sclerosis and Alzheimer's disease. Key trends in the industry include the development of personalized medicine, gene therapies, and immunotherapies. GlobeStar competes with both large pharmaceutical companies and smaller biotech firms in the race to develop more effective treatments for neurological disorders. Competitors include ACUS, AMPE, BIOAF, EHOS, and GBLX.
Who Are GSTC's Key Customers?
- Patients suffering from multiple sclerosis and other neurodegenerative diseases.
- Healthcare providers who prescribe treatments for these conditions.
- Pharmaceutical companies that may be interested in licensing or acquiring GlobeStar's drug candidates.
Financial Health
GlobeStar Therapeutics Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
GSTC Valuation & Market Position
Relative to its peer group, GSTC's quantitative score of 48/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for GlobeStar Therapeutics Corporation stands at 148.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
GlobeStar Therapeutics Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Richland, US. The company is led by CEO James C. Katzaroff. GSTC has traded publicly since 2011.
GSTC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Patented drug formulation.
- Focus on a large and growing market (neurodegenerative diseases).
- Experienced management team.
- Clinical-stage pipeline with potential for future revenue.
Bear Case
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
- No current revenue generation.
- High regulatory risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
GSTC Latest News
No recent news available for GSTC.
GSTC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GSTC.
Price Targets
Wall Street price target analysis for GSTC.
GSTC MoonshotScore
What does this score mean?
The MoonshotScore rates GSTC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: James C. Katzaroff
CEO
James C. Katzaroff serves as the Chief Executive Officer of GlobeStar Therapeutics Corporation. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions in several companies, overseeing clinical trials, regulatory submissions, and strategic partnerships. Katzaroff's expertise lies in guiding early-stage companies through the complex process of bringing new therapies to market. He is responsible for setting the strategic direction of GlobeStar and managing its day-to-day operations.
Track Record: Under James C. Katzaroff's leadership, GlobeStar Therapeutics Corporation has focused on advancing its lead drug candidate through clinical trials. He has overseen the company's efforts to secure patents for its drug formulations and build relationships with key opinion leaders in the field of neurodegenerative diseases. His strategic decisions have been instrumental in positioning GlobeStar as a player in the biotechnology sector.
GSTC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GlobeStar Therapeutics Corporation may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available and may be subject to greater regulatory scrutiny. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not required to meet specific listing standards, resulting in less transparency and potentially higher risk for investors. This tier is often populated by shell companies, bankrupt entities, or companies with questionable operations.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in GSTC.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- The OTC Other tier carries a higher risk of fraud or manipulation.
- GSTC may not meet the listing requirements of major exchanges.
- Potential for delisting or suspension of trading on the OTC market.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Company has a CEO.
- Company is registered in the US.
- Company has a business address.
GlobeStar Therapeutics Corporation Healthcare Stock: Key Questions Answered
What does the AI Score mean for GSTC?
GSTC holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. GlobeStar Therapeutics Corporation is a clinical-stage pharmaceutical company focused on developing treatments for multiple sclerosis and other neurodegenerative diseases. The company's primary …
What does GlobeStar Therapeutics Corporation do?
GlobeStar Therapeutics Corporation is a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapies for neurodegenerative diseases, primarily multiple sclerosis. The company's core focus is on its patented drug formulation, which is currently undergoing clinical trials. GlobeStar aims to address the unmet medical needs of patients suffering from these debilitating conditions by providing more effective and targeted treatments.
What do analysts say about GSTC stock?
As of March 16, 2026, there is no readily available analyst coverage for GlobeStar Therapeutics Corporation (GSTC). Given its status as an OTC-listed, clinical-stage company with a market capitalization of $0.00 billion, it is not widely followed by major investment banks or research firms.
What are the main risks for GSTC?
GlobeStar Therapeutics Corporation faces several significant risks common to clinical-stage biotechnology companies. These include the risk of clinical trial failures, which could halt the development of its lead drug candidate and negatively impact its valuation. Regulatory hurdles and delays in obtaining FDA approval also pose a substantial risk.
What are the key factors to evaluate for GSTC?
GlobeStar Therapeutics Corporation (GSTC) holds an AI score of 48/100 (low). GlobeStar Therapeutics Corporation presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. Not financial advice.
How frequently does GSTC data refresh on this page?
GSTC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GSTC's recent stock price performance?
GlobeStar Therapeutics Corporation (GSTC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Patented drug formulation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GSTC overvalued or undervalued right now?
GlobeStar Therapeutics Corporation (GSTC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GSTC before investing?
Before investing in GlobeStar Therapeutics Corporation (GSTC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for this OTC-listed company.
- AI analysis pending.